BC004004 Inhibitors
Chemical inhibitors of BC004004 exhibit a diverse range of interactions with signaling pathways to exert their inhibitory effects. Staurosporine, a potent protein kinase inhibitor, targets a broad spectrum of kinases that are likely involved in the same pathways as BC004004. By inhibiting these kinases, Staurosporine can disrupt the normal function of BC004004. Similarly, Rapamycin acts on the mTOR protein, a pivotal component of the PI3K/AKT pathway, which BC004004 is a part of. This inhibition can lead to a reduction in BC004004 activity. LY294002 and Wortmannin are both PI3K inhibitors that directly target the PI3K/AKT pathway. The inhibition of PI3K activity can cascade down to BC004004, leading to its functional suppression.
Further along the signaling cascade, PD98059 and U0126 specifically inhibit MEK, an upstream regulator of the ERK/MAPK pathway, which interacts with BC004004. Through the inhibition of MEK, these chemicals can disrupt the activation of BC004004. SB203580 targets p38 MAP kinase within the p38 MAPK signaling pathway, which BC004004 utilizes. Inhibition by SB203580, therefore, translates to decreased BC004004 activity. SP600125 inhibits JNK, another kinase within the signaling network of BC004004, and its inhibition is likely to lead to a decrease in BC004004 activity as well. Imatinib and Gefitinib are tyrosine kinase inhibitors that target BCR-ABL, c-KIT, and EGFR, respectively, which are part of signaling pathways that regulate BC004004. The inhibition of these kinases by Imatinib and Gefitinib results in the functional inhibition of BC004004. Lastly, Triciribine and Bisindolylmaleimide I target AKT and PKC, respectively; both AKT and PKC are key proteins within pathways that BC004004 is involved in, and their inhibition can suppress the function of BC004004.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits a broad range of protein kinases, which may include kinases associated with the signaling pathways that BC004004 is a part of. By inhibiting these kinases, Staurosporine can lead to the inhibition of BC004004. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a key protein in the PI3K/AKT pathway, which is potentially a pathway involving BC004004. Inhibition of mTOR can result in the functional inhibition of BC004004. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor and by inhibiting PI3K, it can inhibit the PI3K/AKT pathway, which BC004004 may be a part of. This leads to a downstream inhibition of BC004004. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin irreversibly inhibits PI3K, which is involved in the PI3K/AKT pathway, a pathway that BC004004 is involved in. This results in the functional inhibition of the BC004004 protein. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK, which is upstream of the ERK/MAPK pathway; BC004004 is known to be involved in this pathway. Inhibition of MEK can thus inhibit the function of BC004004. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that can inhibit the ERK/MAPK pathway. Since BC004004 operates within this pathway, inhibition of MEK by U0126 can lead to functional inhibition of BC004004. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAP kinase, which is involved in the p38 MAPK signaling pathway. As BC004004 is a part of this pathway, inhibition by SB203580 can lead to functional inhibition of BC004004. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, and since BC004004 is involved in the signaling pathways regulated by JNK, this inhibitor can lead to the functional inhibition of BC004004. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib inhibits BCR-ABL and c-KIT, which are tyrosine kinases that could be involved in signaling pathways regulating BC004004. Inhibition by Imatinib can result in functional inhibition of BC004004. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib inhibits EGFR tyrosine kinase, which may regulate BC004004 within the EGFR signaling pathways. As such, its inhibition can functionally inhibit BC004004. | ||||||